+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A Real-World Analysis Of Korean Nation-Wide Database: Pattern, Adherence, And Associated Heatlhcare Costs Of Imatinib Among Patients With Chronic Myeloid Leukemia

A Real-World Analysis Of Korean Nation-Wide Database: Pattern, Adherence, And Associated Heatlhcare Costs Of Imatinib Among Patients With Chronic Myeloid Leukemia

Value in Health 18(7): A434-A435

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 057041791

Download citation: RISBibTeXText

PMID: 26532444

DOI: 10.1016/j.jval.2015.09.1045

Related references

A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. Current Medical Research and Opinion 28(7): 1155-1162, 2013

Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Current Medical Research and Opinion 26(1): 61-69, 2010

Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Current Medical Research and Opinion 26(12): 2861-2869, 2011

Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data. Journal of Medical Economics 20(4): 328-336, 2016

First line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013. Haematologica 2018, 2018

Increasing Burden of Tyrosine Kinase Inhibitor (TKI) Treatment Failure with Later Lines of Therapy (LOT) in Chronic Myeloid Leukemia (CML): A Real World Retrospective Database Analysis. Value in Health 17(3): A78-A79, 2014

Eroltinib Plus Gemcitabine Compared With Gemcitabine Monotherapy In Patients With Pancreatic Cancer: A Real-World Analysis Of Korean Nationa-Wide Database. Value in Health 18(7): A435, 2015

Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib. Leukemia and Lymphoma 56(5): 1385-1391, 2016

Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis. International Journal of Hematology 93(6): 745-749, 2011

Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response. Acta Haematologica 136(1): 45-51, 2016

Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life. Annals of Hematology 2019, 2019

Preliminary validation of self-assessment tool to measure imatinib adherence in patients with chronic myeloid leukemia. PharmacoTherapy 33(2): 152-156, 2013

Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?. Clinical Medicine Insights. Oncology 10: 95-104, 2016

Analysis of imatinib adherence in chronic myeloid leukemia: a retrospective study in a referral hospital in the Brazilian Amazon. Hematology, Transfusion and Cell Therapy 41(2): 106-113, 2019

'Real-life' study of imatinib therapy in chronic phase-chronic myeloid leukemia: A novel retrospective observational longitudinal analysis. Hematology 22(1): 1-8, 2016